Excerpt
In the last decade, heart failure management has evolved significantly, with Sacubitril/Valsartan, an ARNI (Angiotensin Receptor-Neprilysin Inhibitor), emerging as a game-changer. This drug has redefined treatment paradigms by improving survival rates, reducing heart failure hospitalizations, and aiding in the reverse remodeling of the heart. Its dual mechanism of action, targeting both neurohormonal pathways and vasodilation, offers a more comprehensive approach than traditional therapies, marking a significant advancement in heart failure care